News

Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech

CAROLINA is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor. The trial evaluated the cardiovascular safety of Tradjenta (5 mg once daily) compared with

Proleukin is approved in the US for the treatment of metastatic melanoma and metastatic renal cell carcinoma. As per the terms, Clinigen will make an initial payment of

For over a century, the company has developed differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. It is the world leader

Egaten is claimed to be the only FDA-approved drug to treat fascioliasis, which is a neglected tropical disease. Fascioliasis, which is commonly known as liver fluke infestation, is

Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed. LEXETTE is part of the US$600m potent topical corticosteroid

These products, which are often sold on websites and social media platforms, have not been reviewed by the FDA and are not proven safe and effective to treat

The US Court of Appeals for the Federal Circuit (CAFC) has rejected Indivior’s motion to stay issuance of the mandate following its ruling vacating the preliminary injunction (PI)

This collaboration underscores Boehringer Ingelheim’s commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada. Based